Castleark Management’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.4M Buy
+57,760
New +$3.53M 0.09% 183
2015
Q4
– Sell
-178,034
Closed -$3.61M – 417
2015
Q3
$3.61M Sell
178,034
-65,616
-27% -$1.94M 0.12% 206
2015
Q2
$8.08M Buy
+243,650
New +$6.67M 0.22% 132

Other funds holding TVTX

Castleark Management's TVTX Position: Q3 2026 in Review

Castleark Management opened a new position in Travere Therapeutics (TVTX) in Q3 2026: 57,760 shares worth $3.4M. The stake represents 0.09% of the portfolio and ranks #183 among its holdings. This is a return to the name: Castleark Management previously reported a position in TVTX as recently as Q3 2015.

Castleark Management first reported a position in TVTX in Q2 2015 and has held it in 3 quarters since. The position peaked at $8.08M in Q2 2015. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Castleark Management held 57,760 shares of Travere Therapeutics worth $3.4M as of Q3 2026.
  • Travere Therapeutics was a new Castleark Management position in Q3 2026.
  • Travere Therapeutics made up 0.09% of Castleark Management's portfolio in Q3 2026, its #183 holding.
  • Castleark Management first reported a position in Travere Therapeutics in Q2 2015 and has held it in 3 quarters since.
  • Castleark Management's Travere Therapeutics position peaked at $8.08M in Q2 2015.
  • 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Castleark Management's 13F filing for Q3 2026, filed 16 Nov 2026.